Information
At Völur Biotech, our research centers on endophytic microorganisms—the fungi and bacteria that live symbiotically within plant tissues without causing harm. These hidden partners are remarkable biochemical factories, producing secondary metabolites that often mirror or even surpass the pharmacological activities of their host plants.
Hidden partners, novel discoveries
By isolating, characterizing, and optimizing these bioactive compounds, we aim to unlock novel therapeutic agents for use in medicine, nutrition, and sustainable agriculture. Endophyte-derived metabolites exhibit antimicrobial, anticancer, antioxidant, anti-inflammatory, and neuroprotective properties, making them invaluable leads for next-generation drug discovery.
Translating endophyte science
Our approach combines advanced metabolomics, genomics, and computational modeling to elucidate biosynthetic pathways and enhance production yields. Through this, we seek to transform naturally occurring symbioses into scalable biotechnological platforms that replace environmentally taxing synthetic processes and expand the frontiers of natural medicine.
A new molecular economy
In essence, we study endophytes not just for what they are, but for what they can become—a cornerstone of a new era in biopharmaceutical innovation. With a largely undiscovered area of research with a estimated Hundreds of thousands, and possibly millions, of endophyte species remain undiscovered. The vast majority of the world's 300,000 plant species have not been thoroughly studied for their endophyte populations, indicating an immense untapped biological resource.
Dmaq-b1
Our preclinical platform focuses molecular structures like DMAQ-B1, a hydrofluoric acid analog engineered to replicate and enhance insulin activity. Early mice trials demonstrate that DMAQ-B1 can modulate glucose uptake through alternative insulin receptor pathways, effectively stabilizing blood sugar without exogenous insulin injections.
